Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Strategy Inc. (MSTR) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Strategy Inc.Trade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Strategy Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Strategy Inc. trades at $95.2 (market cap $37.84B). The key difference: Strategy Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.

ALNYMSTR
Market Cap
$29.60B$37.84B
Sector
HealthTechnology
52-Week High
$491.22$394.39
52-Week Low
$205.48$82.31
Enterprise Value
$27.56B$56.61B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Strategy Inc.

MSTR trades at $94.83, down 2.57% with bearish technical signals. The company reported Q2 2026 EPS of -$24.45, missing estimates of -$2.19, continuing a trend of significant earnings misses. Despite a 62% analyst buy rating and $210 consensus price target, fundamentals show deep losses with -$3.85B net income and -6,102.96% net margin in 2025. Recent news highlights Bitcoin-related volatility and strategic shifts in the company's treasury management approach.

The outlook remains challenging with persistent operational losses and Bitcoin exposure creating substantial volatility risks. While analyst sentiment is predominantly bullish based on long-term Bitcoin potential, the stock faces fundamental weakness and technical bearish pressure. Investment opportunity exists for those believing in the Bitcoin thesis, but requires tolerance for extreme volatility and ongoing operational underperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR